- Wills, Anne‐Marie;
- Pantelyat, Alexander;
- Espay, Alberto;
- Chan, James;
- Litvan, Irene;
- Xie, Tao;
- Dale, Marian L;
- Gunzler, Steven A;
- Tartaglia, Maria Carmela;
- Fox, Susan H;
- Rodriguez‐Porcel, Federico;
- Sharma, Mansi;
- Lang, Anthony E;
- Boxer, Adam L;
- Group, AL‐108‐231 Study;
- Golbe, Lawrence I
Background
The reliability of the Progressive Supranuclear Palsy Rating Scale (PSPRS) using teleneurology has not been assessed.Objectives
To test whether removing items inadequately assessed by video would impact measurement of PSP severity and progression.Methods
We performed secondary analyses of two data sets: the phase 2/3 trial of Davunetide in PSP and a large single-center cohort. We examined two modifications of the PSPRS: (1) removing neck rigidity, limb rigidity, and postural stability (25 items; mPSPRS-25) and (2) also removing three ocular motor items and limb dystonia (21 items; mPSPRS-21). Proportional agreement relative to the possible total scores was measured using the intraclass correlation coefficient, compared to the original PSPRS baseline values and change over 6 and 12 months. We examined the ability of both scales to predict survival in the single-center cohort using proportional hazards models.Results
The mPSPRS-25 showed excellent agreement (0.99; P < 0.001) with the original PSPRS at baseline, 0.98 (P < 0.001) agreement in measuring change over 6 months, and 0.98 (P < 0.001) over 12 months. The mPSPRS-21 showed agreement of 0.94 (P < 0.001) with the original PSPRS at baseline, 0.92 (P < 0.001) at 6 months, and 0.95 (P < 0.001) at 12 months. Baseline and 6-month change in both modified scales were highly predictive of survival in the single-center cohort.Conclusions
Modified versions of the PSPRS which can be administered remotely show excellent agreement with the original scale and predict survival in PSP. The mPSPRS-21 should facilitate clinical care and research in PSP via teleneurology. © 2022 International Parkinson and Movement Disorder Society.